Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa

Abstract: Background: Adolescents with anorexia nervosa (AN) have low bone density and low levels of surrogate markers of bone formation. Low bone density is a consequence of hormonal alterations that include hypogonadism and decreases in IGF-1, a bone trophic factor. Although IGF-1 is key to pubertal bone accretion, and effects have been demonstrated in adults, there are no data regarding the effect of recombinant human (rh) IGF-1 administration in adolescents with AN. Objectives: We hypothesized that rhIGF-1 would cause an increase in PINP, a bone formation marker, in girls with AN, without any effect on CTX, a bone resorption marker. Subjects and methods: RhIGF-1 was administered at a dose of 30–40 mcg/k twice daily to 10 consecutive girls with AN 12–18 years old for 7–9 days. Ten age-matched girls with AN were followed without rhIGF-1 for a similar period. IGF-1, PINP and CTX levels were measured. Results: RhIGF-1 administration caused an increase in IGF-1 from day-1 to day-4/5 (p <0.0001) and day-1 to day-8/9 (p <0.0001). Simultaneously, PINP increased from day-1 to day-4/5 (p =0.004) and day-1 to day-8/9 (p =0.004), with a smaller increase from day-4/5 to day-8/9 (p =0.048). CTX levels did not change with rhIGF-1 administration. No changes occurred in IGF-1 or PINP levels in girls not receiving rhIGF-1; however, CTX levels increased significantly (p =0.01). Percent change in PINP was significantly higher (p =0.02) and percent change in CTX was significantly lower (p =0.006) in girls who received rhIGF-1 compared to those who did not receive any intervention. RhIGF-1 was well tolerated without hypoglycemia. Conclusion: Short-term administration of rhIGF-1 causes an increase in a surrogate bone formation markers in girls with AN without significant side effects. [Copyright &y& Elsevier]